As Washington Waits On Pricing Proposals, A Call For A Reset In R&D Debate

 
• By Cathy Kelly

Policymakers should clarify link between high drug prices and innovation and figure out how to “rebalance” high prices with non-price innovation incentives before proceeding with policies aimed directly at lowering prices, Conti and David propose in the Health Affairs Blog.

Innovative technologies
Connection Between High Prices, Innovation More 'Nuanced' Than Portrayed

More from Pricing Debate

More from Market Access